Amalgamated Bank’s Protalix BioTherapeutics PLX Stock Holding History

Amalgamated Bank’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2,269	Closed	-$4K	–	2513
2025 Q4	$4K	Sell	2,269 -112	-5%	-$229	﹤0.01%	2805
2025 Q3	$5K	Hold	2,381	–	–	﹤0.01%	2788
2025 Q2	$4K	Buy	+2,381	New	+$4.87K	﹤0.01%	2862
2024 Q2	–	Sell	-1,894	Closed	-$2K	–	3089
2024 Q1	$2K	Sell	1,894 -3,006	-61%	-$4.49K	﹤0.01%	2899
2023 Q4	$9K	Sell	4,900 -563	-10%	-$876	﹤0.01%	2878
2023 Q3	$9K	Hold	5,463	–	–	﹤0.01%	2916
2023 Q2	$11K	Buy	+5,463	New	+$13K	﹤0.01%	2940

Other funds holding PLX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Amalgamated Bank's PLX Position: Q1 2026 in Review

Amalgamated Bank sold out of Protalix BioTherapeutics (PLX) in Q1 2026, closing a stake of 2,269 shares — an estimated $4K sold.

Amalgamated Bank first reported a position in PLX in Q2 2023 and held it in 7 quarters. The position peaked at $11K in Q2 2023. 100 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Amalgamated Bank reported no remaining Protalix BioTherapeutics position as of Q1 2026 after selling out during the quarter.
Amalgamated Bank sold 2,269 Protalix BioTherapeutics shares in Q1 2026, an estimated $4K.
Amalgamated Bank first reported a position in Protalix BioTherapeutics in Q2 2023 and held it in 7 quarters.
Amalgamated Bank's Protalix BioTherapeutics position peaked at $11K in Q2 2023.
100 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.